Cargando…
Differential diagnosis of diarrhoea in patients with neuroendocrine tumours: A systematic review
BACKGROUND: Approximately 20% of patients with neuroendocrine tumours (NETs) develop carcinoid syndrome (CS), characterised by flushing and diarrhoea. Somatostatin analogues or telotristat can be used to control symptoms of CS through inhibition of serotonin secretion. Although CS is often the cause...
Autores principales: | Khan, Mohid S, Walter, Thomas, Buchanan-Hughes, Amy, Worthington, Emma, Keeber, Lucie, Feuilly, Marion, Grande, Enrique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438200/ https://www.ncbi.nlm.nih.gov/pubmed/32874063 http://dx.doi.org/10.3748/wjg.v26.i30.4537 |
Ejemplares similares
-
Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review
por: Cella, David, et al.
Publicado: (2021) -
Circulating tumour cells and tumour biomarkers in functional midgut neuroendocrine tumours
por: Meyer, Tim, et al.
Publicado: (2022) -
Matching-adjusted indirect treatment comparison of [(177)Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [(177)Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours
por: Khan, Mohid S., et al.
Publicado: (2021) -
Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review
por: Grande, Enrique, et al.
Publicado: (2019) -
Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours
por: Rizzo, Francesca M., et al.
Publicado: (2019)